Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05899439 · ClinicalTrials.gov registry record
Immune Function and the Progression to T1D
A clinical trial of Type 1 Diabetes, sponsored by University of Florida.
- Recruiting
- Registry status
- 2,800
- Enrollment target
- 3
- Study locations
NCT05899439: Recruiting study of Type 1 Diabetes, sponsored by University of Florida.
NCT05899439 is a study of Type 1 Diabetes that is actively recruiting participants, run by University of Florida. The registered enrollment target is 2,800 participants, above the 753-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (272% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05899439, a study of Type 1 Diabetes, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- 2,800 participants
- Enrollment target
- 3
- Study locations
Study Summary
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.
Primary Outcome
the number of participants who become at risk for development of type 1 diabetes
Conditions Studied
Interventions
- OTHER blood draw
Study Locations (3)
Florida
- Kieran McGrail - Gainesville
Ohio
- The Ohio State University - Columbus
Texas
- Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,800 participants |
| Start Date | 2005-01-01 |
| Est. Completion | 2085-01-01 |
What NCT05899439 shows while recruiting
NCT05899439 is an observational study that tracks outcomes without assigning an intervention. Its 2,800 participants enrollment target places it among the larger protocols in the corpus, above the 753-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (272% higher).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which blood draw is the first listed.
NCT05899439 reports a single indexed study location in Florida, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05899439 about?
NCT05899439 is a clinical study titled "Immune Function and the Progression to T1D". To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammator...
What is the current status of trial NCT05899439?
This trial is currently recruiting. The enrollment target is 2,800 participants. The study started on 2005-01-01. Estimated completion is 2085-01-01.
What conditions does trial NCT05899439 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT05899439?
The interventions under investigation include: blood draw (OTHER).
Who is sponsoring clinical trial NCT05899439?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05899439 being conducted?
This trial has 3 study locations across Florida, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05899439's enrollment target sits among peer trials
2,800 6th of 198 higher than 193 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
RECRUITING
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
AIDANET Pediatrics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
- NCT06788093 · 2,800 participants · NA
Reducing Overuse of Antibiotics With Decision Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI